Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Jasper Therapeutics completed enrollment of the 18-patient IgA nephropathy cohort of its Phase 2 renal basket study of vensobafusp alfa (KP104), a first-in-class bifunctional complement inhibitor. Initial interim data from the IgAN cohort are expected by year-end 2026, and the company has accelerated an FSGS expansion cohort with first patient dosing anticipated in Q1 2027.
Key figures
- Drug Name
- vensobafusp alfa (KP104)
- Phase Of Trial
- Phase 2
- Dosing cohorts
- Q2W (n=6), Q4W (n=6), Q8W (n=6) subcutaneous maintenance
- Interim data timing
- by year-end 2026
- Igan patients enrolled
- 18
- Fsgs first patient dosing
- Q1 2027
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.